Skip to content
10-K

Annual Report

ALZAMEND NEURO, INC. ALZN

0001214659-25-010763

← back to feed
Filed
Jul 22, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jul 22, 2025 2.9M sh
Shares Diluted FY 2025 · Apr 30, 2025 450.8K sh
Shares Diluted restated FY 2025 · Apr 30, 2024 74.17K sh
Operating Cash Flow FY 2025 · Apr 30, 2025 −$6.57M
Operating Cash Flow FY 2025 · Apr 30, 2024 −$8.27M
Cash And Equivalents FY 2025 · Apr 30, 2025 $3.95M
Cash And Equivalents FY 2025 · Apr 30, 2024 $376.05K
Stockholders Equity FY 2025 · Apr 30, 2025 $3.97M
Stockholders Equity FY 2025 · Apr 30, 2024 −$2.59M
Total Liabilities FY 2025 · Apr 30, 2025 $634.76K
Total Liabilities FY 2025 · Apr 30, 2024 $3.23M
Current Assets FY 2025 · Apr 30, 2025 $4.18M
Current Assets FY 2025 · Apr 30, 2024 $455.24K
Total Assets FY 2025 · Apr 30, 2025 $4.6M
Total Assets FY 2025 · Apr 30, 2024 $631.59K
Eps Diluted FY 2025 · Apr 30, 2025 −$11.32
Eps Diluted restated FY 2025 · Apr 30, 2024 −$132.33
Eps Basic FY 2025 · Apr 30, 2025 −$11.32
Eps Basic restated FY 2025 · Apr 30, 2024 −$132.33
Sga Expense FY 2025 · Apr 30, 2025 $3.08M
Sga Expense FY 2025 · Apr 30, 2024 $3.48M
Rd Expense FY 2025 · Apr 30, 2025 $1.41M
Rd Expense FY 2025 · Apr 30, 2024 $6.46M
Net Income FY 2025 · Apr 30, 2025 −$4.51M
Net Income FY 2025 · Apr 30, 2024 −$9.95M
Operating Income FY 2025 · Apr 30, 2025 −$4.5M
Operating Income FY 2025 · Apr 30, 2024 −$9.94M